-
2023-505964-13-00
5
2021-03-09
Hemophilia A
-
2022-502606-33-00
5
2021-02-26
Patients with histologically or cytologically documented non-squamous
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-511929-60-00
4
2021-01-28
Waldenström’s Macroglobulinemia
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-507153-16-00
5
2020-11-18
Higher-Risk Myelodysplastic Syndrome
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2023-507062-34-00
7
2020-08-07
High-Risk large B-Cell lymphoma
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-511832-29-00
4
2020-08-05
High risk adenocarcinoma of the prostate after radical prostatectomy
(
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-514079-17-00
10
2020-05-28
Endogenous Cushing Syndrome
-
2024-516622-57-00
5
2020-05-06
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Dise